Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-20 @ 12:39 PM
Study NCT ID:
NCT00616551
Status:
COMPLETED
Last Update Posted:
2008-10-08
First Post:
2008-02-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
Sponsor:
Ambrilia Biopharma, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
C2L-OCT-01 PR-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Bonabes de Rouge, M.D./Senior Executive Vice-President & Chief Scientist Officer
Old Organization:
Ambrilia Biopharma, Inc.